Sutab® (sodium sulfate, magnesium sulfate, and potassium chloride tablets; Sebela Pharmaceuticals), an osmotic laxative, is now available for cleansing of the colon in preparation for colonoscopy in adults.
Sutab is a sulfate-based tablet that provides an alternative to liquid-based colonoscopy preparations. The product is administered as a split-dose regimen consisting of 2 doses, the first dose during the evening prior to the colonoscopy and the second during the morning of the colonoscopy.
The approval was based on 2 active-controlled trials which compared the efficacy and safety of Sutab to active comparators in adults undergoing colonoscopy for colorectal cancer screening and surveillance or diagnostic colonoscopy. Both Sutab and the active comparators were administered according to a split-dose regimen. Results from both trials showed that Sutab was noninferior to the active comparators.
“With the introduction of Sutab tablets, we hope to take yet another important step toward removing some of the burden often associated with the preparation process – allowing more patients to feel confident in their choice to undergo a colonoscopy,” said Alan Cooke, President and CEO of Sebela Pharmaceuticals.
Sutab is supplied in cartons containing 2 bottles, each with 12 tablets, as well as a container with a 16-ounce fill line; water must be consumed with each dose and additional water must be consumed after each dose.
The Company is also offering a copay savings card to assist patients.
For more information visit sutab.com.
1. Sebela Pharmaceuticals announces U.S. launch of Sutab® Tablets, an alternative to liquid colonoscopy preparation. [press release]. Roswell, GA: Sebela Pharmaceuticals; January 5, 2021.
2. Sutab [package insert]. Holbrook, MA: Braintree Laboratories, Inc.; 2020.
This article originally appeared on MPR